The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
At least 18 years old and has provided informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.
Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.
Primary central nervous system (CNS) tumors
Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors).
Any conditions that may affect the ability to take or absorb study drug.
Major surgery within 28 days prior to receiving study drug(s).